Adding Induction Chemotherapy Before Chemoradiotherapy with Total Mesorectal Excision and Selective Lateral Lymph Node Dissection for Patients with Poor-Risk, Locally Advanced, Mid-to-Low Rectal Cancer May Improve Oncologic Outcomes: A Propensity Score-Matched Analysis
Tomohiro Yamaguchi(Japanese Foundation For Cancer Research), Tsuyoshi Konishi(Japanese Foundation For Cancer Research), Takashi Sakamoto(Japanese Foundation For Cancer Research), Toshiki Mukai(Japanese Foundation For Cancer Research), Senzo Taguchi(Japanese Foundation For Cancer Research), Akiko Chino(Japanese Foundation For Cancer Research), Yosuke Fukunaga(Japanese Foundation For Cancer Research), Toshiya Nagasaki(Japanese Foundation For Cancer Research), Kensei Yamaguchi(Japanese Foundation For Cancer Research), Yukiharu Hiyoshi(Japanese Foundation For Cancer Research), Eiji Shinozaki(Japanese Foundation For Cancer Research), Takashi Akiyoshi(The Japanese Society of Gastroenterological Surgery)
Cited by 11
Related Papers
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
|The Lancet Oncology|2021|411
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
|Nature Medicine|2020|366
Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system
|Cancer Science|2014|238